Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154451 | 0.87 | TSHR (0.59) | TSHRPOLBSORT1HTTALDH1A1 | |
| SCHEMBL13085841 | 0.85 | SMN1; SMN2 (0.50) | HTTALDH1A1SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL11940936 | 0.85 | SMN1; SMN2 (0.50) | HTTALDH1A1SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL12927387 | 0.85 | SMN1; SMN2 (0.50) | HTTALDH1A1SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL9420603 | 0.85 | TSHR (0.57) | TSHRPOLBSORT1HTTALDH1A1 | |
| SCHEMBL10575131 | 0.80 | SMN1; SMN2 (0.41) | TSHRPOLBHTTALDH1A1CASP1 | |
| SCHEMBL22163985 | 0.80 | CA12 (0.52) | TSHRHTTALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL10825837 | 0.77 | ALDH1A1 (0.56) | TSHRPOLBHTTALDH1A1TP53 | |
| SCHEMBL2818580 | 0.77 | CA1 (0.57) | TSHRPOLBHTTALDH1A1TP53 | |
| SCHEMBL68449 | 0.76 | ALDH1A1 (0.61) | TSHRPOLBHTTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-20220009909-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-01-13 | — | — | US | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019202052-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-0709377-B1 | Process for producing quinolin-2-yl benzoic acid compounds | ASAHI GLASS CO LTD (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5780634-A | Process for producing 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds | THE GREEN CROSS CORPORATION (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0709377-A1 | Process for producing quinolin-2-yl benzoic acid compounds | ASAHI GLASS COMPANY LTD. (JP) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TSHR 4691/4885POLB 4407/4885SORT1 3463/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | TSHR 4691/4885POLB 4407/4885SORT1 3463/4885 |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | TSHR 4181/4885POLB 4198/4885SORT1 3339/4885 |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | TSHR 3243/4885POLB 2381/4885SORT1 3500/4885 |
| US-20220009909-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | TSHR 4278/4885POLB 4094/4885SORT1 2945/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TSHR 4691/4885POLB 4407/4885SORT1 3463/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | TSHR 3246/4885POLB 2502/4885SORT1 3664/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | TSHR 3246/4885POLB 2502/4885SORT1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.